Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site

Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses

(2012) Slava Stamova et al.   ANALYTICAL BIOCHEMISTRY

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies

(2012) P. A. Erba et al.   JOURNAL OF NUCLEAR MEDICINE

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies

(2010) Michael Fiechter et al.   ATHEROSCLEROSIS

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives

(2009) Roland Stork et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

(2008) M. Amann et al.   CANCER RESEARCH

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE